CJC-1295 vs CJC-1295 without DAC

Both are tetrasubstituted analogues of GHRH(1-29); the difference is the Drug Affinity Complex. CJC-1295 with DAC binds serum albumin and stays active for days, while Mod GRF 1-29 (often called "CJC-1295 without DAC") lasts minutes and produces a short, pulse-like GH release.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

CJC-1295

A long-acting synthetic analogue of growth-hormone-releasing hormone (GHRH) carrying a Drug Affinity Complex that binds serum albumin.

BEST STUDIED FOR

GH secretagogues

Read the cited profile →

🧪

CJC-1295 without DAC

A stabilised 29-amino-acid GHRH fragment with four amino-acid substitutions — the short-acting cousin of CJC-1295 with DAC.

BEST STUDIED FOR

GH secretagogues

Read the cited profile →

SIDE BY SIDE

	CJC-1295	CJC-1295 without DAC
The key difference	Drug Affinity Complex extends half-life to days	No DAC — half-life of minutes
Class	GH secretagogues	GH secretagogues
Mechanism	CJC-1295 is a modified GHRH(1-29) sequence acting on the pituitary GHRH receptor.	GHRH(1-29)-NH2 is the shortest fully active portion of GHRH.
Status	Early clinical pharmacology only: placebo-controlled studies in healthy adults characterised its pharmacokinetics and GH/IGF-1 response in the mid-2000s; no approved medicine. It is monitored as a prohibited substance in anti-doping science.	GHRH(1-29) analogues were studied clinically from the 1980s (GH secretion, paediatric growth). The modified version circulates as a research peptide and has been found in seized doping material.
Reported safety signals	The healthy-volunteer studies reported it was generally well tolerated over the study period. Recent sports-medicine reviews stress the absence of long-term safety data and the variable quality of unregulated product.	Older GHRH(1-29) studies reported short-term tolerability; GHRH analogues are prohibited in sport.
A key study	Two randomised, placebo-controlled studies in healthy adults characterised CJC-1295 pharmacokinetics and reported dose-dependent, prolonged increases in GH and IGF-1. (J Clin Endocrinol Metab 2006, PMID 16352683)	Measured GH responses to GHRH(1-29)-NH2 and a D-Ala2-substituted analogue in normal men across a dose range. (Peptides 1985, PMID 2866496)

WHEN TO RESEARCH WHICH

Research questions about sustained GH/IGF-1 elevation point to CJC-1295 with DAC; questions about preserving natural pulsatility point to Mod GRF 1-29. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[CJC-1295] Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — J Clin Endocrinol Metab 2006. PMID 16352683
[CJC-1295] Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects — Growth Horm IGF Res 2009. PMID 19386527
[CJC-1295] Advances in the detection of growth hormone releasing hormone synthetic analogs — Drug Test Anal 2021. PMID 34665524
[CJC-1295 without DAC] Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men — Peptides 1985. PMID 2866496
[CJC-1295 without DAC] Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies — J Med Chem 1998. PMID 9513600
[CJC-1295 without DAC] Glycine-modified growth hormone secretagogues identified in seized doping material — Drug Test Anal 2019. PMID 30136411

FREQUENTLY ASKED

What is the difference between CJC-1295 and CJC-1295 without DAC?

What is the regulatory status of CJC-1295 and CJC-1295 without DAC?

CJC-1295: Early clinical pharmacology only: placebo-controlled studies in healthy adults characterised its pharmacokinetics and GH/IGF-1 response in the mid-2000s; no approved medicine. It is monitored as a prohibited substance in anti-doping science. CJC-1295 without DAC: GHRH(1-29) analogues were studied clinically from the 1980s (GH secretion, paediatric growth). The modified version circulates as a research peptide and has been found in seized doping material.

What safety signals have been reported?

CJC-1295: The healthy-volunteer studies reported it was generally well tolerated over the study period. Recent sports-medicine reviews stress the absence of long-term safety data and the variable quality of unregulated product. CJC-1295 without DAC: Older GHRH(1-29) studies reported short-term tolerability; GHRH analogues are prohibited in sport.

Which studies is this comparison based on?

For CJC-1295: “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults” (PMID 16352683); “Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects” (PMID 19386527); “Advances in the detection of growth hormone releasing hormone synthetic analogs” (PMID 34665524). For CJC-1295 without DAC: “Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men” (PMID 2866496); “Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies” (PMID 9513600); “Glycine-modified growth hormone secretagogues identified in seized doping material” (PMID 30136411).